Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 15/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.47 |
| ▸ | USP2 | O75604 | 8/20 | 0.47 |
| ▸ | TSHR | P16473 | 5/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18212474 | 0.95 | CYP2D6 (0.52) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL18926696 | 0.92 | CYP3A4 (0.56) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL24751941 | 0.91 | CYP3A4 (0.51) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL13400658 | 0.91 | CYP3A4 (0.51) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL18926690 | 0.91 | CYP2D6 (0.56) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL17285924 | 0.90 | CYP2D6 (0.47) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL19969931 | 0.90 | CYP3A4 (0.50) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL18926689 | 0.88 | CYP2D6 (0.68) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL22878340 | 0.88 | CYP2D6 (0.46) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL24847484 | 0.88 | CYP2D6 (0.46) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KYRAS THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KRAS, HRAS, NRAS | CYP2D6 4831/4885SMN1; SMN2 4055/4885CYP3A4 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.